DFTX — Definium Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-04-27.
Performance
Technicals
Others in Healthcare
Measured signals that fired on DFTX
| date | signal | measured base rate |
|---|---|---|
| 2026-08-06 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-30 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-06-26 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-06-22 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-22 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-04-10 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-12 | Sullivan Mark Chief Legal Officer | Grant or award | 62.5K | 0.00 | 0 |
| 2026-08-12 | Barrow Robert Chief Executive Officer | Grant or award | 375.0K | 0.00 | 0 |
| 2026-08-12 | Karlin Daniel Chief Medical Officer | Grant or award | 100.0K | 0.00 | 0 |
| 2026-08-12 | Roberts Brandi Chief Financial Officer | Grant or award | 62.5K | 0.00 | 0 |
| 2026-08-12 | Wiley Matthew T. Chief Commercial Officer | Grant or award | 62.5K | 0.00 | 0 |
| 2026-06-25 | Barrow Robert Chief Executive Officer | Open-market sale 10b5-1 plan | 29.2K | 45.03 | 1.3M |
| 2026-06-25 | Sullivan Mark Chief Legal Officer | Open-market sale 10b5-1 plan | 13.0K | 45.03 | 585.8K |
| 2026-06-25 | Karlin Daniel Chief Medical Officer | Open-market sale 10b5-1 plan | 10.0K | 45.03 | 451.9K |
| 2026-06-25 | Roberts Brandi Chief Financial Officer | Open-market sale 10b5-1 plan | 3.0K | 45.03 | 135.7K |
| 2026-06-25 | Wiley Matthew T. Chief Commercial Officer | Open-market sale 10b5-1 plan | 2.9K | 45.03 | 129.1K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 160.3M | 8.5M |
| Driehaus Capital Management LLC | 111.7M | 5.9M |
| Avoro Capital Advisors LLC | 94.5M | 5.0M |
| JANUS HENDERSON GROUP PLC | 67.2M | 3.6M |
| Deep Track Capital, LP | 56.7M | 3.0M |
| GEODE CAPITAL MANAGEMENT, LLC | 47.2M | 2.5M |
| STATE STREET CORP | 46.7M | 2.5M |
| Octagon Capital Advisors LP | 46.1M | 2.4M |
| Commodore Capital LP | 37.8M | 2.0M |
| FMR LLC | 34.2M | 1.8M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 4 | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 4 | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 4 | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 4 | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 4 | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 8-K | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Definium Therapeutics, Inc. (DFTX) filed form 8-K · 2026-08-12 · SEC EDGAR
- Definium Therapeutics stock jumps 20% on Phase 3 trial results · 2026-08-12
Ask the AI about DFTX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →